{
    "clinical_study": {
        "@rank": "138044", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1 (Treatment A/B)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be randomised to receive Treatment A in Period 1 followed by Treatment B in period 2"
            }, 
            {
                "arm_group_label": "Sequence 2 (Treatment B/A)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be randomised to receive Treatment B in Period 1 followed by Treatment A in period 2"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to evaluate the effect of repeated oral doses of AZD1722 on the pharmacokinetics of\n      Cefadroxil"
        }, 
        "brief_title": "To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "A Phase 1, Single-center, Randomized, 2-Way Cross-over, Open-label Study to Evaluate the\n      Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Cefadroxil in\n      Healthy Volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:- 1. Healthy male and female volunteers aged \u226518 years to \u226450 years\n        (inclusive) with suitable veins for cannulation or repeated venepuncture 2. Females could\n        be of non-childbearing potential and child bearing potential Females of non-child bearing\n        potential should be Post-menopausal, documentation of irreversible surgical sterilization\n        by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.\n        Females of childbearing potential must have a negative pregnancy test at screening and\n        must not be lactating, using one of the following effective methods to avoid pregnancy\n        during the treatment periods, must have an established use of oral, injected, or implanted\n        hormonal methods of contraception, placement of an intrauterine device (IUD) or\n        intrauterine system, use a barrier method of contraception: condom or occlusive cap\n        (diaphragm or cervical/vault caps) with spermicidal. Male healthy volunteers with a\n        partner of childbearing potential must agree to avoid fathering a child, and refrain from\n        donating sperm, from the first day of dosing until at least 3 months after last dose of\n        investigational product, and therefore be either sterile (with the appropriate\n        post-vasectomy documentation of the absence of sperm in the ejaculate) or agree to use,\n        one of the following approved methods of contraception: a male condom with spermicide; a\n        sterile sexual partner or use by female sexual partner of an acceptable form of effective\n        contraception (see above) 3. Have a body mass index (BMI) \u226518 and \u226430 kg/m2 and weigh at\n        least 50 kg and no more than 100 kg Exclusion Criteria: 1.History of any clinically\n        significant disease or disorder which, in the opinion of the principal investigator, may\n        either put the healthy volunteer at risk because of participation in the study, or\n        influence the results or the healthy volunteer's ability to participate in the study.\n        2.History or presence of GI, hepatic or renal disease including GI surgery other than\n        appendectomy or any other condition known to interfere with absorption, distribution,\n        metabolism or excretion of drugs. 3.Any clinically significant illness, medical/surgical\n        procedure or trauma within 4 weeks of the first administration of the investigational\n        product. 3 History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity,\n        as judged by the principal investigator or history of hypersensitivity to drugs with a\n        similar chemical structure or class to AZD1722 or cefadroxil. 4. Has received another new\n        chemical entity (defined as a compound which has not been approved for marketing) or has\n        participated in any other clinical study that included drug treatment within at least 30\n        days of the first administration of investigational product in this study. 5. Loose stools\n        for \u22652 days in the past 7 days before investigational product administration. Use of\n        medications that are known to affect stool consistency and/or GI motility, including fibre\n        supplements, anti diarrheals, prokinetic drugs, enemas, probiotic medications or\n        supplements; or salt or electrolyte supplements containing sodium, potassium, chloride, or\n        bicarbonate formulations during the past 7 days before randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140281", 
            "org_study_id": "D5613C00004"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1 (Treatment A/B)", 
                    "Sequence 2 (Treatment B/A)"
                ], 
                "description": "A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1", 
                "intervention_name": "Treatment A (cefadroxil alone)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1 (Treatment A/B)", 
                    "Sequence 2 (Treatment B/A)"
                ], 
                "description": "15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil", 
                "intervention_name": "Treatment B -  AZD1722 followed by cefadroxil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cefadroxil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Phase I, Healthy Volunteers", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Single-center, Randomized, 2-Way Cross-over, Open-label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Cefadroxil in Healthy Volunteers", 
        "other_outcome": {
            "description": "Description of the safety profile in terms of adverse events, vital signs, electrocardiogram, hematology, clinical chemistry, urinalysis and physical examination.", 
            "measure": "To evaluate the safety profile when cefadroxil is administered after AZD1722 in terms of adverse events, vital signs, electrocardiogram, hematology, clinical chemistry, urinalysis and physical examination", 
            "safety_issue": "Yes", 
            "time_frame": "Safety assessments performed through the screening period (Day -28) to 10 days after the last dose in Period 2"
        }, 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Quintiles Drug Research Unit Call Centre", 
            "phone": "0800 634 1132"
        }, 
        "overall_official": {
            "affiliation": "Quintiles, Overland Park, Kansas", 
            "last_name": "Eleanor - Lisbon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in plasma area under the concentration-time curve (AUC) and maximal plasma concentration (Cmax) of cefadroxil after AZD1722 administration.", 
            "measure": "To evaluate the pharmacokinetics of cefadroxil when administered after AZD1722 by assessment of area under the concentration-time curve (AUC) and maximal plasma concentration (Cmax) of cefadroxil", 
            "safety_issue": "No", 
            "time_frame": "Blood sampling for cefadroxil: Predose, 0.5 hour, 1, 1.5, 2, 2.5, 4, 6, 8, 10, and 12 hours postdose on Day 1 in Treatment A and on Day 5 in Treatment B"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate plasma concentrations of AZD1722 to be measured (no PK parameters derived)", 
                "measure": "To evaluate the plasma concentrations of AZD1722", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling for AZD1722: Predose, 1, 2, and 4 hours postdose, on Day 5 (Treatment B)"
            }, 
            {
                "description": "Pharmacodynamic outcome of the effect on stool consistency and frequency", 
                "measure": "To evaluate the pharmacodynamic outcomes of AZD1722 by the assessment of how AZD1722 effects stool consistency and frequency", 
                "safety_issue": "No", 
                "time_frame": "Stool frequency and stool consistency will be measured daily (24-hour period intervals) on Day -1 through Day 1 (Treatment A) and Day 1 through Day 5 (Treatment B)"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}